Theorysuit, your assertion is that NWBO's low SP is driven by market forces reacting to what you perceive as Management incompetence. Your evidence for this is the length of time that has elapsed "since 2018 without DCVax-L's commercialisation and the absence of any new clinical trials" (presumably indicating Managerial incompetence in not advancing the DCVax family).
My claim is that the low SP is due to the activities of malign 3rd parties suppressing the share price, presumably because it is to their financial benefit and/or in an attempt to remove a serious challenge to their own existence.
Your claim is evidenced by 2 statements: "Trial ended in 2018. It is now 2026. Has nwbo commercialized this drug or run any new trials since?" However, no facts are provided to link your evidence to the low SP although "Market Forces" could play an obvious role. There is nothing, however, to show that your evidence is the cause of the low SP and not the result of the low SP. This is a good example of the well established principle that "Correlation does not imply causation".
The way I see it is that neither the lack of commercialisation nor the absence of clinical trials have caused the low SP. On the lack of commercialisation after so long a time, I think that it is conceivable that progress might have been speedier and that submission of the Marketing Authorisation Application (MAA) (December 2023) might have come sooner but there is no evidence for or against this possibility. It is a question for later when all the Boardroom details are known.
As for the absence of new Clinical Trials, that can be laid firmly on the relative poverty of NWBO due to the paucity of incoming funds from commercial sales. Low SP is the cause of the lack of clinical trials and not a consequence. Start-ups like NWBO usually have to fund clinical trials by borrowing from commercial entities whose interest rates are inversely proportional to their SPs - the lower the SP the higher the rate of interest. That is why there has been no follow up trials involving DCVax-Direct - the NWBO cannot afford them, something the Company has publicly acknowledged repeatedly in its regulatory filings and disclosures - that it needs to raise substantial additional capital in order to fund its clinical trials.
My hypothesis is that the low SP is caused by malevolent 3rd parties who are depressing the SP for their own financial betterment and derives from such evidence as follows. This evidence is fact-based from publicly accessible documentation.
1] Market Makers and Hedge Funds have been (and still are) targeting NWBO to keep the SP as low as possible by "Spoofing" the shares over an extended period. This is an illegal practice and evidence of its use the practice has been collected by NWBO over a long period and involves at least 7 major Market Makers. It is now before the Courts of Justice and is well-based so much so that the Judge has declined to accept a "Motion to Dismiss" submitted by the Defendants. This indicates that legally there is substance in the claims so that the case must go ahead.
2] One of the strongest bits of evidence to demonstrate that the SP is being driven down by blatantly illegal means and not by market force is how the SP responded on Tuesday, 10th May, 2022 when the results of the Phase 3 Clinical Trial were announced publicly at a conference hosted by the New York Academy of Sciences. From the advance publication list of attendees at the conference (which included all NWBO's big-wigs) it was obvious that the trial had succeeded (a failure would not have warranted such a public announcement.). From the start of the week preceding the conference (and before the list of known attendees was published) the SP on the Monday rose from $0.70 to $1.06 at close on the Friday (after the names of attendees were known) and then the SP opened at $2.05 on the Tuesday of the announcement. It then began falling, even before the conference began, to a nadir of $0.386, a fall of 80%. This was due to spoofing on the day. For example, 13 of 29 spoofing incidents by Citadel Securities occurred even prior to the data being presented with a further 11 executed whilst the actual presentation was in progress. It wasn’t just Citadel that indulged in spoofing to portray the DCVax-L trial as a failure. It was all 7 of the Defendants in the legal case. There was even one Hedge Fund boss who tweeted during the presentation that the trial had failed. Helping the process along was Adam Feuerstein who was also cited in the Defendants’ Joint Memorandum of Law in Support of the Motion to Dismiss.
In my turn, I would ask you if you can refute this?
AI
